Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis

(2010) Nicolas Clere et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

(2008) Joel B. Nelson et al.   CANCER

A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer

(2008) A. J. Armstrong et al.   CLINICAL CANCER RESEARCH

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

(2008) Nicholas D. James et al.   EUROPEAN UROLOGY

Endothelin-1 enhances the expression of the androgen receptor via activation of the c-mycpathway in prostate cancer cells

(2008) June G. Lee et al.   MOLECULAR CARCINOGENESIS